Stanford researchers to present early results on study using GutCheck Patch™ at DDW

February 24, 2017

Researchers at Stanford University Hospital, led by Brendan Visser MD and Monica Dua MD, will present results from a study using G-Tech Medical’s GutCheck Patch™ system to study gastrointestinal function in patients recovering from Whipple surgery at Digestive Disease Week in Chicago on May 9, 2017.  

The Whipple procedure, or pancreaticoduodenectomy, is used to treat resectable pancreatic cancer.  As it is a major form of surgery, patients remain hospitalized for a median of 9 days.A key driver of overall recovery and discharge from the hospital involves performance of the GI tract.  As motor activity function returns to stomach, small intestine and colon, patients are able to be fed an increasingly normal diet, beginning with clear liquids, then full liquids and finally progressing to solid foods.  The earlier patients are fed the sooner they regain health, but knowing when a patient is ready is currently difficult to determine, typically limited by highly subjective information.  The GutCheck Patch™ system reads electrical signals from the major organs and continuously monitors their levels of motor activity from soon after surgery until they are ready to leave the hospital.  In the GI tract, motor activity patterns are direct signs of organ function.  In the future it is anticipated the GutCheck Patch™ system will enable better informed decision-making surrounding feeding timing and type, leading to better health, shortened hospital stays, and lower costs.

El Camino Hospital launches GutCheck Patch™ system Clinical Trial

Mountain View, California - March 18, 2016

El Camino Hospital is pleased to announce it is a site for a medical device trial for the GutCheck System by G-Tech Medical, which records the electrical signals that naturally occur in the digestive tract (also called the gastrointestinal or GI tract) and patterns of intestinal contractions and movements in individuals who undergo surgery. 

The pilot/feasibility study “Measurement of Gastrointestinal Myoelectric Activity in Patients At Risk For or Who Have a Post-Operative Ileus” uses the GutCheck System, comprised of a wireless, wearable, disposable patch and app, to measure the electrical activity from the stomach, small intestine and colon. The study will retrospectively look for differences in the patterns of patients who develop an ileus (also called an intestinal pseudo-obstruction) and patients who have normal return of GI activity following surgery that could be used to predict who might develop ileus.

El Camino Hospital will be the first site to trial the GutCheck System by G-Tech Medical, a Company in Residence at the Fogarty Institute for Innovation located on the hospital’s campus. The two-year trial is expected to enroll 80 study participants at El Camino Hospital. Participation in the trial is open to adult patients who undergo an open or laparoscopic GI surgery. During the participant’s hospital stay, a GutCheck patch will be placed on the patient’s abdominal skin to measure the natural electrical activity in the GI tract following surgery. The electrical activity will be transmitted to a mobile device and cloud server for frequency analysis.

“Post-op ileus is a common problem following abdominal surgery that can cause abdominal pain, nausea, vomiting and other morbidities in patients. It extends their hospital stays and adds thousands of dollars of cost to their care, while increasing the risk of readmission,” said Steve Axelrod, PhD, President and CEO of G-Tech Medical. “If proven effective, the GutCheck system's ability to monitor stomach and intestinal motor activity continuously and non-invasively could help physicians detect the onset of ileus at an early stage and help minimize these highly undesirable effects.”

The National Institutes of Health estimates between 60 and 70 million Americans experience diseases that affect the digestive system. Functional Gastrointestinal Disorders (FGID) constitute a majority of all GI problems, which lead to over 40 million office visits annually. Although they are not life threatening, FGIDs often greatly impact the lives of those afflicted and cannot be diagnosed with existing tests like colonoscopy, CT scans or other imaging. The GutCheck System hopes to analyze the electrical activity frequencies of the digestive organs under normal conditions to help pinpoint the source and nature of dysfunction to help physicians better target therapies and provide faster relief and at a lower cost for patients.

“The testing of the GutCheck System at El Camino Hospital showcases our leadership in innovative care and provides our patients with the latest options in digestive care,” said George Triadafilopoulos, MD, principal investigator for GutCheck System trial at El Camino Hospital. “We continuously seek new devices and procedures to help us provide leading-edge, personalized care for our patients.”

About El Camino Hospital

El Camino Hospital is an acute-care, 443-bed, nonprofit and locally governed organization with campuses in Mountain View and Los Gatos, California. Key medical specialties include cancer, heart and vascular, men’s health, mental health, neuroscience, orthopedic and spine, senior health, urology, and the first Women's Hospital in Northern California. The hospital is recognized as a national leader in the use of health information technology and wireless communications, and has been awarded the Gold Seal of Approval from The Joint Commission as a Primary Stroke Center as well as three consecutive ANCC Magnet Recognitions for Nursing Care. To learn more visit


G-Tech presented data at the American Gastroenterological Association's 2015 James W. Freston Conference: A Renaissance in the Understanding and Management of IBS.

August 29, 2015

The American Gastroenterological Association hosted the 2015 James W. Freston Conference: A Renaissance in the Understanding and Management of IBS on Aug. 29 and 30, 2015 in Chicago, IL. The meeting brought together more than 215 leading experts in IBS research and patient care to explore the latest insights on diagnosing and phenotyping IBS patients. G-Tech's Anand Navalgund presented the abstract titled "Feasibility of measuring the contractile electrical complex over 72 hours in a healthy human subject using a wearable, wireless electrode patch" at the meeting. 

G-Tech has presented results previously, including three posters at the American College of Gastroenterology Meeting in Philadelphia in October, 2014. While the technology employed in the previous clinical research could collect and record patient data for only three hours in an office setting with the patient sitting still, the new prototype can record continuously for three days while the patient goes about normal daily activities. In the workmpresented at the AGA conference, researchers observed an intriguing correlation between myoelectric signal peaks and meal and bowel movements, a correlation made possible by the system’s ability to collect continuous, long-term data. The ability to collect 72 hours of data without interfering with the patient’s daily life represents a significant advancement. 

G-Tech invited to provide 'The GI Startup Perspective' at the 2015 AGA Tech Summit: Fostering Innovation & Technology in Digestive and Metabolic Diseases 

March 20, 2015

G-Tech CEO Steve Axelrod gave an invited talk at the March 20, 2015 American Gastroenterology Association's annual meeting of its Center for GI Innovation and Technology (CGIT), entitled “Perspective of the Startup” in the final session of the conference. Companion presentations in the wrap-up session were “Perspective of the GI”, by Dr. Michael Camilleri, Mayo Clinic Professor of Medicine and President-elect of the AGA, and “Perspective of the Surgeon”, by Dr. Jeffrey Marks, Program Director of General Surgery at Cleveland’s UH Case Medical Center.  

After describing the G-Tech wireless patch and the company’s vision for its use in diagnosing functional GI disorders, Axelrod spoke about the importance of early adopters in the GI community, the role the CGIT can play in both helping bring new innovations to market, and in partnering with the FDA and insurance payers to establish the clinical data necessary to secure regulatory clearance and reimbursement.

G-Tech is the winner of the 2014 HealthTech Showcase Superstar contest organized by the American Diabetes Association (ADA).

Nov 14, 2014

G-Tech is the winner of the 2014 HealthTech Showcase Superstar contest organized by the American Diabetes Association (ADA). Among the 70 companies that competed for the honor, G-Tech was one of the 5 finalists that was chosen to present at the 19th annual ADA Silicon Valley Leaders Forum Luncheon held at the Sofitel Hotel, Redwood Shores on Nov 14, 2014. G-Tech was voted as the winner of the contest by the audience that comprised of over 450 Bay Area executives with representatives from the biotech, venture capital and investment community.

G-Tech presented three abstracts at the American College of Gastroenterology's 79th Annual Scientific Meeting

 October 19, 2014

G-Tech started an IRB approved single-arm, non-randomized feasibility study in October 2012. The study was designed to transcutaneously detect and monitor myoelectric intestinal signals temporally associated with the symptoms of patients who report pain and have suspected or diagnosed IBS, and in controls [subjects without suspected IBS or diagnosis of IBS and prior and/or current complaints of pain].  We have tested over 70  patients and controls as part of the study. Data from this trial was submitted and accepted to be presented as posters at the 79th annual meeting of the American College of Gastroenterology in Philadelphia

About ACG

More than 12,500 physicians from 86 countries are members of the ACG. Through annual scientific meetings, The American Journal of Gastroenterology, regional postgraduate training courses and research grants, the ACG provides its members with the most accurate and up-to-date scientific information on digestive health and the etiology, symptomatology and treatment of GI disorders. ACG’s advocacy in the public policy arenas, and the work of the ACG’s 22 committees have made tremendous strides with many premiere accomplishments to improve the future of clinical gastroenterology and the quality of care available to patients with GI conditions and diseases, today. The information exchange and training acquired through College membership provide physicians with the knowledge necessary to offer the most effective patient care and to meet the challenges of today’s changing health care system.

For more information, click here.

NetScientific invests in a further two Breakout Labs portfolio companies

July 23, 2014

NetScientific plc (AIM:NSCI, 'NetScientific' or 'The Group'), the biomedical and healthcare technology investment group, is pleased to announce it has made a further two investments in portfolio companies from Breakout Labs, Peter Thiel's revolving philanthropic fund that supports early-stage companies working on technological breakthroughs.

 G-Tech Medical is developing a wireless, wearable, disposable patch, which will help diagnose the root causes of Functional Gastrointestinal Disorders ('FGIDs').  FGIDs afflict more than 60 million people annually in the US, and are a large burden to the health care system.  The G-Tech patch will measure and characterize the activity of the main digestive organs under normal daily conditions to help pinpoint the source of the dysfunction.  It will allow physicians to quickly determine that a functional problem exists, in many cases allowing them to skip the current invasive, expensive anatomic testing sequence.  By identifying the specific source and nature of the dysfunction it will enable them to more effectively target their therapies, bringing relief to patients faster and at lower cost. 

 Longevity Biotech is developing an entirely new approach to therapeutics development via artificial protein technology ("Hybridtides"). Hybridtides® are peptide molecules that contain both α- and β-amino acid subunits, which makes them resistant to breakdown by natural digestive enzymes, tunable to very stable conformations, and able to mimic information-rich surfaces displayed by natural proteins or peptides, enabling new drug designs which are more stable and more clinically active. Current work will establish the platform's potential in a clinically important indication in cardiovascular disease, pulmonary arterial hypertension. 

 The new investments represent the first outside financing for both G-Tech and Longevity Biotech. 

Farad Azima, CEO of NetScientific commented:

"We are delighted to continue working with Breakout Labs in their quest to identify and foster revolutionary life science companies at the forefront of scientific innovation.  Longevity Biotech and G-Tech Medical are two such examples of innovative technologies in areas of clinical importance which will transform the lives of patients."






Contact Us

Fogarty Institute for Innovation

2490 Hospital Drive, Suite 310,

Mountain View, CA 94040

G-Tech Medical 

© G-Tech Inc.  All rights reserved 

Not Approved For Sale